glp 1 biosimilar Trends to watch: GLP-1 drugs, biosimilars, PBM lawsuit GLP 1 Drug Biosimilar Market

A major shift is coming to the GLP-1 weight loss drug market in 2026 one that could dramatically change who can access these medications, how theyre taken, and how much they cost.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have a welcome benefit in addition to weight loss and glycemic control, with new data pre...

Medicare is now covering weight loss drugs for some people

hazard ratio 0.71, 0.52 to 0.98), whereas serious renal events generated a wide confidence interval (1.4 v 2.0 events per 1000 person years

United by a shared mission to enhance obesity care, MYOS focuses on advancing clinical practice, raising awareness, and sharing expertise to improve the lives of people affected by obesity.